HebeCell Corp (“HebeCell”) today announced that it has closed a US$10 million Pre-Series A financing to further advance the research and development of its leading patented scalable natural killer (NK) cell platform technology. Aceso Biotech Venture Fund invested in this round of financing.
The design of HebeCell’s 3D NK cell manufacture platform mimics lymph node environments of NK cell development in vivo. Compared to other currently available systems, our platform has 6 major technical advantages.